PCOS Is Now PMOS: What This Major Change Means For Women

Maybe your endocrinologist mentioned it at your last appointment. Maybe a women's health account in your feed posted about it. Maybe a friend who reads The Lancet for fun forwarded you the headline. Polycystic ovary syndrome (PCOS) — the condition you were diagnosed with, or suspect you have, or have been managing for years — has a new name. It's now polyendocrine metabolic ovarian syndrome (PMOS).

If your first reaction was "great, one more thing to keep track of," that's reasonable. If your second reaction was "wait — is what I have still what I have?", that's the question this article exists to answer.

The short version: yes. The condition didn't change. The label changed because the old label was actively misleading clinicians and patients, and a global consensus of 56 medical organizations decided that the costs of keeping it outweighed the costs of renaming it (Teede et al. 2026). The diagnostic criteria you were assessed against, the symptoms you experience, the treatments that work — all carry over. What changes is the lens. PMOS names what the condition actually is at the level of biology: a multisystem endocrine and metabolic disorder that happens to involve the ovaries, not an ovarian disease that happens to disturb metabolism. That distinction sounds academic until you realize it dictates which specialist sees you, which tests get ordered, and which treatments get tried first.

Here's what changed, what stayed the same, and how to navigate the transition without losing the thread of your own care.

What was wrong with the name "polycystic ovary syndrome"?

The original name had three specific problems that compounded over four decades of clinical practice.

First, the "cysts" the name referred to are not cysts. The ovaries in PCOS — now PMOS — do not typically contain true pathological cysts. They contain an accumulation of small, arrested follicles: eggs that began to develop but stalled before ovulation. On ultrasound these look like a string of pearls along the ovary's edge, which is why early imaging studies described them as cysts and the name stuck. The biology is different. A cyst is a fluid-filled sac that shouldn't be there. A follicle is a structure that should be there, doing a job (maturing an egg), failing to finish the job. The treatment implications are different too, because cysts get drained or removed while arrested follicles get coaxed back into normal cycling through hormonal and metabolic interventions.

Second, polycystic ovarian morphology — many small follicles visible on ultrasound — is common in healthy women, especially adolescents whose endocrine systems are still maturing. Up to a quarter of women in their teens and twenties will have ovaries that meet the old ultrasound criteria for PCOS without having the condition. Under the old framework, this created a steady stream of overdiagnoses in young women who were told they had a chronic syndrome when they actually had a normal developmental pattern that would resolve on its own.

Third — and this is the diagnostic and treatment cost that drove the rename — calling it an "ovary syndrome" anchored clinical care in gynecology. If the disease is an ovary disease, the default specialist is a gynecologist and the default treatment is something that acts on the ovaries, which in practice means the birth control pill. The pill manages symptoms downstream of the ovaries: it suppresses ovulation, stabilizes cycles, often clears androgen-driven acne by raising sex hormone-binding globulin (SHBG, a protein in your blood that binds up loose testosterone). What it does not do is address the metabolic dysfunction that is driving most of those symptoms in the first place. A generation of women were prescribed the pill in their late teens, told their PCOS was being managed, and discovered in their thirties that their insulin resistance, weight pattern, and fertility concerns had been quietly progressing the whole time.

The "polycystic ovary" framing pulled care away from the part of the body where most of the actual disease lives.

What does "polyendocrine metabolic ovarian syndrome" mean?

The new name unpacks into four words that each carry weight.

The word "polyendocrine" means multiple endocrine systems are involved. Endocrine = hormone-producing. In PMOS the dysfunction isn't confined to ovarian hormones. The brain's hormone-pacing circuit is disrupted. The pancreas is producing too much insulin. The adrenal glands often produce excess androgens (male-type hormones) independently of the ovaries. The liver is making less SHBG than it should, which lets more loose testosterone circulate. Each of these is its own endocrine axis, and PMOS involves all of them at once. "Polyendocrine" names that.

"Metabolic" means the condition is at its core a metabolic disorder. The clinical symptoms you experience — irregular cycles, unwanted facial or body hair growth, jawline acne, weight gain centered at the middle — track downstream of how your body handles glucose, insulin, fats, and inflammation. In roughly 70% of cases, insulin resistance is the primary driver (Diamanti-Kandarakis & Dunaif 2012). Even in the cases where insulin isn't the lead actor, inflammation or adrenal-stress hormones are — also metabolic, also systemic. The reproductive symptoms are the visible end of a metabolic problem.

"Ovarian" stayed in the name because that's where the diagnostic pattern most reliably shows up. The ovaries are where the diagnostic ultrasound is performed; ovulation status (regular vs. irregular cycles) is the most accessible clinical signal of dysfunction; and elevated anti-Müllerian hormone (AMH, a hormone made by your follicles) — now used as a blood-test alternative to ultrasound — is an ovarian marker. The consensus panel considered alternatives. "Reproductive" was rejected because it can cause severe social stigmatization in cultures where fertility carries high value, and because it overstated the condition's role in reproductive identity. "Ovulatory" was rejected because it was too narrow — the term loses relevance after menopause, when many women still have the underlying metabolic dysfunction that defined their condition for decades.

"Syndrome" stayed because that's what it is: a cluster of symptoms with shared mechanisms but no single defining lesion or mutation. Different women have different presentations, different drivers, different lab patterns. Calling it a syndrome — rather than a disease — leaves room for that heterogeneity, which is clinically important when designing a treatment plan.

The result is a name that describes what the condition actually is at the level of biology: a multi-axis hormone and metabolic disorder, named for the organ system where the diagnosis lands most reliably, recognized as a syndrome rather than a single disease.

Why did they finally change it now?

The rename wasn't a quick decision. The Lancet consensus published in 2026 was the output of a multi-year, multistep global process involving 56 leading academic, clinical, and patient organizations and processing over 14,360 stakeholder survey responses (Teede et al. 2026). Modified Delphi methods and nominal group technique workshops were used to surface consensus across specialties — endocrinology, reproductive medicine, primary care, nutrition, psychology, and patient advocacy were all at the table.

Three things had to converge for the rename to happen.

The mechanistic evidence had to be overwhelming. Forty years of research after the original naming made it clear that insulin resistance, hyperandrogenism (excess androgens), and the central hormone-pacing dysfunction were the primary drivers — not the ovarian morphology that gave the condition its name. Studies on GnRH pulse dysregulation, hepatic SHBG suppression, theca cell androgen overproduction, and the brain-pancreas-ovary feedback loop had accumulated to the point where the ovary-centric framing was an obvious mismatch with the biology (Goodarzi et al. 2011).

The diagnostic infrastructure had to be ready. AMH testing — a blood test for the same hormone the granulosa cells in arrested follicles overproduce — has matured to the point where it can substitute for transvaginal ultrasound as a diagnostic criterion in adults (Dewailly et al. 2011). That mattered for the rename because it reduced the diagnostic reliance on the "polycystic" ultrasound finding that the old name pointed at. With AMH as an alternative, the diagnostic process is no longer ovary-imaging-centric.

The patient-advocacy momentum had to be there. Years of patient surveys, advocacy organizations, and clinical observation had documented the harms of the old name: women dismissed because their ovaries looked normal on imaging despite obvious clinical symptoms; women told they had PCOS based on adolescent ultrasounds and treated indefinitely without re-evaluation; women whose insulin resistance and cardiovascular risk went unaddressed because their gynecologist was focused on cycle management. The consensus panel weighted patient experience explicitly in the renaming process.

To prevent disruption to clinical care, the consensus established a three-year evolutionary transition. The new nomenclature is being integrated into electronic health records, the International Classification of Diseases (ICD), and the planned 2028 update of the International Guidelines. During this transition, both PCOS and PMOS appear in clinical settings; medical records may use either; insurance and billing systems are updating in parallel.

What stayed the same?

If you read past the rename announcement and stopped there, you might assume more changed than actually did. Most of the clinical infrastructure carries over unchanged.

The diagnostic criteria are the same. Adult diagnosis still relies on the revised Rotterdam criteria, which require meeting two of three features: clinical or biochemical signs of androgen excess (acne, unwanted hair growth, hair loss, or elevated testosterone on bloodwork); irregular or absent menstrual cycles; and polycystic ovaries on ultrasound or elevated AMH on bloodwork. If you were diagnosed under PCOS, you carry the same diagnosis under PMOS. No retesting is needed.

Your treatment plan doesn't reset. Combined oral contraceptives, spironolactone, metformin, inositol supplementation, letrozole for fertility — every existing evidence-based intervention works on the same mechanism it did before the rename. If your protocol was working, it still works.

Your symptoms map to the same patterns. Insulin resistance still drives the most common form (roughly 70% of cases). Adrenal androgen excess still accounts for around 10% of cases. Inflammatory and post-pill subtypes still exist as clinical patterns. The Rotterdam phenotypes (A through D, describing different combinations of the three diagnostic criteria) still organize the formal nosology.

Your lab tests stay relevant. Fasting insulin, fasting glucose, HOMA-IR (a calculated index from fasting insulin and glucose that measures how insulin-resistant you actually are), total and free testosterone, DHEA-S (a hormone your adrenal glands make), SHBG, AMH, 17-OHP for ruling out the genetic adrenal differential — every test that mattered before still matters.

The lived experience is unchanged. The chin acne that flares the week before your period, the strands you find in the shower drain that didn't used to be there, the way one missed cycle quietly becomes three, the bloating, the energy dips after lunch — the body is doing what it was doing. The label on the body changed.

What's the actual biology underneath the name?

Because the rename foregrounds the multisystem nature of the condition, this is the part of the picture that matters most to understand. The clinical symptoms you experience are driven by a reinforcing loop between four systems: your brain's hormone-pacing circuit, your ovaries, your pancreas, and your adrenal glands.

The disruption starts centrally with the signaling network between your brain and your ovaries. The hypothalamus releases gonadotropin-releasing hormone — the part of your brain that paces hormone signals — in pulses. The timing of those pulses dictates what the pituitary gland does next: rapid pulses promote luteinizing hormone (LH), the hormone that tells your ovaries to make testosterone; slower pulses favor follicle-stimulating hormone (FSH), the signal that helps follicles mature. In PMOS the pulse frequency is abnormally high, which drives LH up while FSH stays normal or slightly suppressed. That LH/FSH imbalance is the signature pattern on bloodwork (McCartney & Campbell 2020).

Elevated LH acts on the theca cells of your ovaries, stimulating them to overproduce androgens — including testosterone and androstenedione. This excess local testosterone physically slows the development of your ovarian follicles. They begin to mature, then arrest before completing the process. Because the follicles don't mature, ovulation doesn't happen. As these small, arrested follicles accumulate, their granulosa cells secrete high levels of AMH — typically two to three times higher than normal in PMOS. That elevated AMH counteracts the brain's signal to recruit new follicles and reduces aromatase (the enzyme that converts androgens to estrogens), which traps the ovary in a high-androgen, arrested state. This is why your period disappears or becomes highly irregular.

Insulin resistance amplifies this whole loop. Your muscle and fat cells stop responding to insulin the way they should, so your pancreas makes more of it to compensate. For a while this works and your blood sugar stays normal. The cost is steadily rising insulin levels in your bloodstream, and that high circulating insulin is the part driving most of the symptoms you are feeling. It worsens the androgen burden through two distinct mechanisms.

First, insulin directly enhances the effect of LH on your ovarian theca cells, pushing them to manufacture even more testosterone. Second, metabolic dysfunction drastically reduces your liver's production of SHBG. In a healthy state, SHBG tightly binds testosterone and dihydrotestosterone (DHT — a stronger form of testosterone), leaving only 1 to 2 percent unbound and biologically active. When your SHBG drops, more testosterone is free to circulate and drive symptoms like jawline acne and hair thinning. Recent evidence indicates that this SHBG reduction isn't just caused by insulin directly — it's driven by liver fat accumulation and inflammatory chemicals released by belly fat (Diamanti-Kandarakis & Dunaif 2012). Low-grade inflammation creates a tight, self-reinforcing loop between metabolic dysfunction, liver health, and reproductive failure.

Parallel to all of this, the adrenal pathway runs on its own track. Your adrenal glands produce DHEA-S — a hormone your adrenals make — under the control of your brain's stress signal (ACTH), not insulin or LH. In about 10% of cases, isolated DHEA-S elevation is the primary androgen driver while ovarian testosterone and insulin sensitivity are entirely normal. DHEA-S itself is relatively weak, but your peripheral tissues can convert it into testosterone and DHT, producing the same physical symptoms as the ovarian-driven form.

This is what "polyendocrine" actually points at: four hormone-producing systems working out of synchrony, each contributing to the clinical pattern, with different women weighted toward different drivers. The 2026 rename foregrounds the multisystem framing because the diagnostic and treatment implications track from which axis is the primary driver in your specific case.

What changes about how I'll be diagnosed or treated?

Some things shift, even though the diagnostic criteria themselves are stable.

The reliance on pelvic ultrasound is decreasing. The revised criteria allow AMH testing as a diagnostic proxy for ultrasound in adults — diagnosis via blood draw rather than imaging. To prevent overdiagnosis, clinical guidelines specify that a patient should be tested via ultrasound or AMH, but not both (Teede et al. 2023). For adolescents, ultrasound is now completely excluded from diagnostic criteria, because multifollicular ovaries are normal during endocrine maturation. Adolescents must present with both irregular cycles and clear, severe signs of androgen excess to be diagnosed — a higher bar that reduces overdiagnosis in teenagers.

Metabolic assessment is taking center stage. The American Diabetes Association explicitly recommends regular diabetes screening for patients with the condition, particularly those with body mass index over 25. Clinically, severe insulin resistance often presents visibly as acanthosis nigricans — dark, velvety patches on the back of your neck, armpits, or groin. Biochemically, your clinician should be looking beyond just fasting glucose. A HOMA-IR score above 2.0 to 2.5 indicates probable insulin resistance long before your HbA1c (a three-month average of your blood sugar) reaches prediabetic levels. The shift to "metabolic" in the name nudges clinicians to order this panel earlier and act on insulin findings before glucose itself starts to drift.

For patients presenting with the adrenal pattern — high DHEA-S, normal ovarian testosterone, normal insulin sensitivity — guidelines require ruling out a genetic condition called nonclassic congenital adrenal hyperplasia (NCAH). NCAH looks almost identical to adrenal-driven PMOS clinically but is caused by a partial deficiency of the 21-hydroxylase enzyme, which bottlenecks cortisol production and shunts precursors into the androgen synthesis pathway. The screening test is an early-morning blood draw measuring 17-hydroxyprogesterone (17-OHP); if borderline, an ACTH stimulation test confirms (Carmina et al. 2017).

For symptom management, the protocols have continued to evolve.

For patients seeking pregnancy, the first-line medical treatment to induce ovulation is no longer clomiphene citrate; it is letrozole, an aromatase inhibitor. Letrozole temporarily blocks the conversion of androgens into estrogens, which removes negative feedback on your brain and prompts an increase in FSH secretion, driving ovarian follicle maturation. A meta-analysis of 42 RCTs covering 7,935 women showed letrozole produces higher live birth rates than clomiphene without increased risk of ovarian hyperstimulation (Franik et al. 2018). The landmark NICHD multicenter trial that drove this shift showed cumulative live birth rates of 27.5% with letrozole versus 19.1% with clomiphene (Legro et al. 2014).

For cycle management without pregnancy intent, combined oral contraceptives remain a first-line option, but the specific progestin matters. The pill works in part by stimulating your liver to produce more SHBG, which binds up excess testosterone. Older progestins like levonorgestrel have intrinsic androgenic properties and bind to SHBG themselves, which pushes testosterone back into its free, active state — and can actively worsen acne and hair growth. Modern PMOS management uses third- or fourth-generation progestins (like drospirenone) that have minimal SHBG affinity and directly block androgen receptors.

For severe hirsutism (unwanted facial or body hair growth) and hair loss, spironolactone is used to block androgen receptors at the hair follicle (Farquhar et al. 2003). For metabolic management, metformin activates cellular pathways that allow your muscles to take up glucose independent of insulin, lowering circulating insulin levels and indirectly reducing testosterone production.

For inositol — the supplement most women with PMOS will hear about — the ratio matters. In PMOS, high insulin disrupts how your body processes inositol, depleting the specific form your ovaries actually need to mature follicles. Supplementation using a physiological 40:1 ratio of myo-inositol to D-chiro-inositol restores metabolic and hormonal parameters faster than myo-inositol alone, improving insulin sensitivity without impairing oocyte quality (Nordio & Proietti 2012). A systematic review of myo-inositol RCTs found improvements in ovulatory function and hyperandrogenism markers across studies (Unfer et al. 2012).

For mild hyperandrogenism, spearmint tea has the strongest botanical evidence base. A randomized controlled trial of 42 hirsute women drinking spearmint tea twice daily for 30 days showed a significant drop in free testosterone with reduced subjective hirsutism scoring (Grant 2010). The original mechanism study showed decreased free testosterone with increased LH, FSH, and estradiol in hirsute women (Akdoğan et al. 2007).

The treatment lineup is largely the same as it was; what changes is the priority order. Under the old framework, ovary-focused interventions (the pill, ovulation induction) often led. Under the new framework, the metabolic interventions move earlier in the clinical reasoning, especially for the 70% of patients whose insulin resistance is the primary driver.

What about the four-subtype framework — does it still apply?

Among Functional Medicine and integrative-nutrition practitioners, a four-subtype framework — insulin-resistant, post-pill, inflammatory, and adrenal — is commonly used to guide targeted lifestyle and dietary interventions. This framework isn't a formally peer-reviewed diagnostic classification, but it maps usefully onto the Rotterdam phenotypes and helps women and their clinicians think through which mechanism is the primary driver in their case.

The insulin-resistant subtype is the most common, accounting for roughly 70% of cases. This is the classic metabolic presentation where hyperinsulinemia (high circulating insulin) drives ovarian theca cell androgen production and suppresses hepatic SHBG. It maps to Rotterdam phenotypes A and B. The biology and treatment approach are explored in depth in our insulin-resistance PCOS article.

The adrenal subtype accounts for around 10% of cases — isolated DHEA-S elevation with normal ovarian testosterone and normal insulin sensitivity. This is the presentation that explains why some women have severe acne and hair loss despite "normal" testosterone bloodwork. It runs on the ACTH-cortisol-DHEA-S axis rather than the insulin-LH axis. The mechanism and management approach is covered in our adrenal PCOS article.

The inflammatory subtype describes patients with androgen excess and ovulatory dysfunction who lack primary insulin resistance. Chronic systemic inflammation — often stemming from gut permeability, autoimmune conditions like Hashimoto's thyroiditis, or chronic mast cell activation — drives ovarian androgen synthesis. The clinical and dietary approach for this presentation is detailed in our inflammatory PCOS article.

The post-pill subtype describes a temporary, withdrawal-induced state rather than a chronic syndrome. When you discontinue combined oral contraceptives — particularly those with highly anti-androgenic progestins — you can experience a temporary surge in androgen production while the hypothalamic-pituitary-ovarian axis recalibrates. This presentation typically resolves within three to six months. Our post-pill PCOS article covers what to expect during the recalibration.

The rename to PMOS doesn't change the validity of these subtype distinctions. If anything, the "polyendocrine" framing makes the heterogeneity more explicit — different women have different primary drivers, and the treatment plan should track which axis is driving the presentation.

When should I use which term?

In daily life and in your own self-advocacy, this depends on context.

With your current clinician, use whichever term they use. If your endocrinologist still says PCOS, you say PCOS — that's the in-room shorthand. If they've shifted to PMOS, you shift with them. Both terms will appear in clinical settings for the next several years.

On lab orders and medical records, the ICD coding is in transition. You may see PCOS, PMOS, or both on your paperwork. Don't worry about the inconsistency; the underlying diagnosis is unchanged.

In support communities and online research, expect to see PCOS dominate for the foreseeable future. Patient-facing search volume hasn't shifted yet, and a lot of the best research, support groups, and educational resources use the old term. When you're searching, search PCOS — you'll find more.

In medical-literature contexts — when you're reading research papers published after 2026, or talking with a clinician who specializes in this area — you'll see PMOS more often. The 2028 International Guidelines update will accelerate this.

With Tamika's resources here at Nourished Natural Health, you'll see both terms layered. Article titles often carry both — PCOS for query-match (that's what you typed into the search bar that brought you here), PMOS as acknowledgment of where the medical literature now sits. Article bodies are PCOS-anchored because that's where most readers are. The disclaimer block at the top of every PCOS article links back to this rename pillar for context.

You don't have to switch your vocabulary. The term you've been using is still correct. The condition you've been managing is still the condition you've been managing.

What should I take away from this rename?

Three things.

The first is that this is validation, not invention. Women have been reporting for decades that their PCOS wasn't just a fertility issue — that the metabolic, mood, sleep, and weight effects were as much a part of the lived condition as the cycle disruption. The medical literature has been catching up to that for the better part of twenty years. The PMOS rename is the formal acknowledgment that the catch-up is complete.

The second is that the rename is permissive, not directive. You don't have to relearn your condition. You don't have to update your vocabulary. Your existing diagnosis stands; your existing treatment plan, if it's working, keeps working. What the rename does is open more doors — it makes it easier to advocate for the metabolic workup that should accompany the reproductive workup, and it gives you a vocabulary for the next conversation with a clinician who treats PCOS as a gynecology issue.

The third is that the underlying biology is what matters, not the label. Whether you call it PCOS or PMOS, the questions to ask your clinician are the same: What's my fasting insulin and HOMA-IR? Is my androgen excess driven by my ovaries, my adrenals, or both? Am I in the insulin-resistant majority or one of the smaller subtypes? What's my long-term cardiometabolic risk and what's the surveillance plan? If you understand the specific endocrine and metabolic drivers of your presentation, you can build a targeted, effective protocol — under either name.

If you're at the start of that conversation, the PCOS diagnosis and diet article walks through what testing to ask for, what dietary approach maps to which subtype, and how to read the results. If you're further along and trying to identify which subtype matches your presentation, the insulin-resistance, adrenal, inflammatory, and post-pill articles each go deep on one driver and what to do about it.

The name changed. The work doesn't.